Efficacy of three different budesonide treatments in Chinese preschool children with recurrent wheezing.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
    • Abstract:
      To explore and compare the clinical control of three atomized inhalation budesonide (BUD) regimens for Chinese preschool children with recurrent wheezing using Test for Respiratory and Asthma Control (TRACK) scores. A total of 474 preschool children with positive Modified Asthma Predictive Index (mAPI) were randomly assigned to a daily group (initially given inhaled BUD 1 mg once a day and assessed every 4 weeks; if symptom were well controlled for 12 weeks, the dose was reduced to 25-50% of the previous dose until afinal dose of 0.25 mg once a day, maintained until 52 weeks), an intermittent high-dose group (1 mg twice daily for 7 days starting early during a predefined respiratory tract illness) and an intermittent medium-dose group (0.5 mg twice daily as soon as they contacted allergens or experienced nasal congestion, a runny nose, cough or other suspicious respiratory symptoms and continuing until symptoms were reduced or risk factors were absent for 3 days) for 52 weeks of treatment. The TRACK questionnaire was administered every 4 weeks. When TRACK scores were ≥ 80, symptoms were considered to be controlled. The average TRACK scores of the three groups after treatment were significantly higher than those before treatment (P < 0.001). There were no significant differences in the average TRACK scores and control rate after treatment at every 4 weeks in the three groups (P > 0.05). Te number of systemic glucocorticoid courses, urgent care visits for wheezing, and wheezing episodes before and after treatment were significantly different within each of the three groups (P < 0.001), but not among the three groups (P > 0.05). In clinical treatment of children, one of the three treatment options can be selected according to the specific situation case of mAPI- positive recurrent wheezing children.
      (© 2022. The Author(s).)
    • References:
      J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):1-8; quiz 9-10. (PMID: 26772922)
      Pediatrics. 2016 Jun;137(6):. (PMID: 27230765)
      J Allergy Clin Immunol. 2011 Nov;128(5):983-8. (PMID: 21906790)
      Lancet. 2014 May 3;383(9928):1593-604. (PMID: 24792856)
      J Asthma. 2014 Jun;51(5):530-5. (PMID: 24494666)
      N Engl J Med. 2011 Nov 24;365(21):1990-2001. (PMID: 22111718)
      Transl Pediatr. 2016 Jan;5(1):31-6. (PMID: 26835404)
      Allergol Immunopathol (Madr). 2018 May - Jun;46(3):210-217. (PMID: 27865539)
      Allergol Immunopathol (Madr). 2018 Mar - Apr;46(2):190-195. (PMID: 29331617)
      Exp Ther Med. 2019 Oct;18(4):3090-3094. (PMID: 31555389)
      BMC Pediatr. 2019 Nov 5;19(1):411. (PMID: 31684902)
      Pediatrics. 2011 Mar;127(3):e737-47. (PMID: 21339276)
      J Allergy Clin Immunol. 2014 Jan;133(1):111-8.e1-13. (PMID: 23891353)
      J Allergy Clin Immunol. 2009 Apr;123(4):833-9.e9. (PMID: 19348922)
      Patient Prefer Adherence. 2019 Jul 31;13:1325-1334. (PMID: 31534319)
      J Allergy Clin Immunol Pract. 2013 Mar;1(2):152-6. (PMID: 24187656)
    • Accession Number:
      0 (Glucocorticoids)
      51333-22-3 (Budesonide)
    • Publication Date:
      Date Created: 20221011 Date Completed: 20221013 Latest Revision: 20240905
    • Publication Date:
      20240905
    • Accession Number:
      PMC9553874
    • Accession Number:
      10.1038/s41598-022-21505-9
    • Accession Number:
      36220847